Component
Gastrointestinal adverse events during lipoic-acid exposure
Gastrointestinal adverse events during lipoic-acid exposure. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Nausea, vomiting and vertigo increased with dose in SYDNEY 2.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/17065669.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519", "start_char": 0, "end_char": 1756, "text_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519"}
- experimental_model
- SYDNEY 2 randomized double-blind placebo-controlled trial
- exposure
- Oral ALA 600, 1200 or 1800 mg/day for five weeks
- limitations
- Short-term symptom endpoint; no proof of nerve regeneration, lifelong benefit or correction of a nutritional deficiency.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- Higher studied doses did not simply mean a better tolerated response.
- primary_references
- [ala-p17065669] Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. (2006). https://pubmed.ncbi.nlm.nih.gov/17065669/ DOI: 10.2337/dc06-1216
- tissue_or_cell_type
- 181 participants with diabetic distal symmetric polyneuropathy
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1131–1142
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · SYDNEY 2 randomized double-blind placebo-controlled trial · source_derived_draft · unverified_draft
### ala-sydney2-adverse-events Nausea, vomiting and vertigo increased with dose in SYDNEY 2. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: Higher studied doses did not simply mean a better tolerated response. organism: Human tissue_or_cell_type: 181 participants with diabetic distal symmetric polyneuropathy experimental_model: SYDNEY 2 randomized double-blind placebo-controlled trial limitations: Short-term symptom endpoint; no proof of nerve regeneration, lifelong benefit or correction of a nutritional deficiency. exposure: Oral ALA 600, 1200 or 1800 mg/day for five weeks evidence_span: {"source_cache": "artifacts/ala-research/17065669.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519", "start_char": 0, "end_char": 1756, "text_sha256": "3a54016cad3453fec96e99aa5906435793d7baaddaf5254d5ce335aac5bb4519"} [ala-p17065669] Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. (2006). https://pubmed.ncbi.nlm.nih.gov/17065669/ DOI: 10.2337/dc06-1216
Complete structured claim and evidence
Where it participates (unsigned role)
The R-only period had fewer gastrointestinal event reports than the racemate period; the mean symptom-score difference was not statistically significant.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/32212340.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "44984e6b01b34f66b48a24660a08befba9fc1691954a6832010d6ec01df29220", "start_char": 0, "end_char": 1654, "text_sha256": "44984e6b01b34f66b48a24660a08befba9fc1691954a6832010d6ec01df29220"}
- experimental_model
- Crossover study in 20 people with progressive multiple sclerosis
- exposure
- 600 mg R-lipoic acid versus 1200 mg racemic lipoic acid over 7–10 days
- limitations
- Equal nominal R content but different total doses; short tolerability/PK study, not an efficacy comparison.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- One tolerability measure favored R-only, but the score comparison was inconclusive.
- primary_references
- [ala-p32212340] Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. (2020). https://pubmed.ncbi.nlm.nih.gov/32212340/ DOI: 10.1002/jcph.1605
- tissue_or_cell_type
- Plasma and gastrointestinal symptom reports
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 702–713
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Crossover study in 20 people with progressive multiple sclerosis · source_derived_draft · unverified_draft
### ala-r-racemate-gi The R-only period had fewer gastrointestinal event reports than the racemate period; the mean symptom-score difference was not statistically significant. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: One tolerability measure favored R-only, but the score comparison was inconclusive. organism: Human tissue_or_cell_type: Plasma and gastrointestinal symptom reports experimental_model: Crossover study in 20 people with progressive multiple sclerosis limitations: Equal nominal R content but different total doses; short tolerability/PK study, not an efficacy comparison. exposure: 600 mg R-lipoic acid versus 1200 mg racemic lipoic acid over 7–10 days evidence_span: {"source_cache": "artifacts/ala-research/32212340.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "44984e6b01b34f66b48a24660a08befba9fc1691954a6832010d6ec01df29220", "start_char": 0, "end_char": 1654, "text_sha256": "44984e6b01b34f66b48a24660a08befba9fc1691954a6832010d6ec01df29220"} [ala-p32212340] Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. (2020). https://pubmed.ncbi.nlm.nih.gov/32212340/ DOI: 10.1002/jcph.1605
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.